{"id":4168,"date":"2022-02-04T21:15:26","date_gmt":"2022-02-04T20:15:26","guid":{"rendered":"https:\/\/www.mc-praha.cz\/mcp\/?p=4168"},"modified":"2022-02-04T21:16:07","modified_gmt":"2022-02-04T20:16:07","slug":"paxlovid-novy-peroralni-lek-proti-covid-19","status":"publish","type":"post","link":"https:\/\/www.mc-praha.cz\/mcp\/paxlovid-novy-peroralni-lek-proti-covid-19\/","title":{"rendered":"Paxlovid \u2013 nov\u00fd peror\u00e1ln\u00ed l\u00e9k proti COVID-19"},"content":{"rendered":"<p>Firma Pfizer zavr\u0161ila v\u00fdvoj sv\u00e9 nejnov\u011bj\u0161\u00ed zbran\u011b proti COVID-19. Jedn\u00e1 se o l\u00e9k s vysokou \u00fa\u010dinnost\u00ed proti viru SARS-CoV-2 s\u00a0obchodn\u00edm n\u00e1zvem Paxlovid. Toto antivirotikum je ur\u010deno k\u00a0or\u00e1ln\u00edmu pod\u00e1n\u00ed a v\u00fdrobce deklaruje jeho vysok\u00fd efekt sni\u017euj\u00edc\u00ed riziko hospitalizace a \u00famrt\u00ed pacient\u016f s COVID-19. L\u00e9k Paxlovid se pou\u017e\u00edv\u00e1 u rizikov\u00fdch dosp\u011bl\u00fdch pacient\u016f ke sn\u00ed\u017een\u00ed pravd\u011bpodobnosti t\u011b\u017ek\u00e9ho pr\u016fb\u011bhu onemocn\u011bn\u00ed COVID-19 za p\u0159edpokladu, \u017ee od propuknut\u00ed nemoci ub\u011bhlo maxim\u00e1ln\u011b 5 dn\u00ed a stav pacienta nevy\u017eaduje oxygenoterapii. Riziko hospitalizace by m\u011bl tento l\u00e9k sn\u00ed\u017eit a\u017e o 90 %.<\/p>\n<p>Paxlovid obsahuje samostatn\u00e9 tablety dvou l\u00e9\u010div\u00fdch l\u00e1tek \u2013 nirmatrelviru a ritonaviru, kter\u00e9 je doporu\u010deno pod\u00e1vat 2x denn\u011b po dobu 5 dn\u016f. Inhibice proteinu 3CL nirmatrelvirem blokuje \u0161t\u011bpen\u00ed polyproteinov\u00fdch prekurzor\u016f, co\u017e zabra\u0148uje mno\u017een\u00ed viru v organismu. Ritonavir zpomaluje rozpad nirmatrelviru, kter\u00fd tak m\u016f\u017ee z\u016fstat v t\u011ble d\u00e9le v\u00a0pot\u0159ebn\u00e9 koncentraci \u00fa\u010dinn\u00e9 proti viru.<\/p>\n<p>Jedna ze studi\u00ed na 499 pacientech, kter\u00fdm byl Paxlovid pod\u00e1v\u00e1n po dobu 5 dn\u016f, zaznamenala jeho 89% \u00fa\u010dinnost. Uk\u00e1zalo se, \u017ee l\u00e9k sni\u017euje virovou n\u00e1lo\u017e oproti placebu a\u017e desetin\u00e1sobn\u011b. Tak\u00e9 se prok\u00e1zala vysok\u00e1 \u00fa\u010dinnost proti \u0159ad\u011b variant viru SARS-CoV-2 (alfa, beta, delta, lambda, m\u00ed, gama i omikron).<\/p>\n<p>Jako u ka\u017ed\u00e9ho nov\u00e9ho l\u00e9ku, velk\u00e1 pozornost mus\u00ed b\u00fdt v\u011bnov\u00e1na jeho vedlej\u0161\u00edm \u00fa\u010dink\u016fm a zejm\u00e9na interakc\u00edm jeho \u00fa\u010dinn\u00fdch slo\u017eek s\u00a0jin\u00fdmi l\u00e9ky.<\/p>\n<p>L\u00e9k Paxlovid, doned\u00e1vna schv\u00e1len\u00fd pro pou\u017eit\u00ed jen v\u00a0USA a Velk\u00e9 Brit\u00e1nii, obdr\u017eel 28.1. 2022 podm\u00edne\u010dnou registraci platnou v cel\u00e9 EU a m\u016f\u017ee se tak jako prvn\u00ed ofici\u00e1ln\u011b schv\u00e1len\u00e9 peror\u00e1ln\u00ed antivirotikum proti SARS-CoV-2 za\u010d\u00edt pod\u00e1vat ve v\u0161ech \u010dlensk\u00fdch st\u00e1tech v\u010detn\u011b \u010cesk\u00e9 republiky.<\/p>\n<p>Ing. V\u00edt Smejkal<\/p>\n<p>3.2.2022<\/p>\n<p>&nbsp;<\/p>\n<p>Zdroje:<\/p>\n<p>Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring addressed to member states for unauthorised product Paxlovid (PF-07321332 150 mg and ritonavir 100 mg) available for use. (2021).\u00a0Dostupn\u00e9 na:\u00a0https:\/\/ema.europa.eu\/en\/documents\/referral\/paxlovid-pf-07321332-ritonavir-covid-19-article-53-procedure-conditions-use-conditions-distribution_en.pdf<\/p>\n<p>Pfizer announces additional phase 2\/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or death.\u00a0<em>Pfizer<\/em>, (2021). Dostupn\u00e9 na:\u00a0https:\/\/businesswire.com\/news\/home\/20211214005548\/en\/Pfizer-Announces-Additional-Phase-23-Study-Results-Confirming-Robust-Efficacy-of-Novel-COVID-19-Oral-Antiviral-Treatment-Candidate-in-Reducing-Risk-of-Hospitalization-or-Death<\/p>\n<p>Paxlovid \u2013 Assessment report. EMEA\/H\/A-5(3)\/1513. (2021). Dostupn\u00e9 na:\u00a0<em><a href=\"http:\/\/www.ema.europa.eu\/en\/documents\/referral\/paxlovid-pf-07321332-ritonavir-covid-19-article-53-procedure-assessment-report_en.pdf\">https:\/\/ema.europa.eu\/en\/documents\/referral\/paxlovid-pf-07321332-ritonavir-covid-19-article-53-procedure-assessment-report_en.pdf<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Firma Pfizer zavr\u0161ila v\u00fdvoj sv\u00e9 nejnov\u011bj\u0161\u00ed zbran\u011b proti COVID-19. Jedn\u00e1 se o l\u00e9k s vysokou [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"image","meta":{"_uag_custom_page_level_css":""},"categories":[1],"tags":[],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"boldthemes_grid":false,"boldthemes_grid_11":false,"boldthemes_grid_22":false,"boldthemes_grid_21":false,"boldthemes_grid_12":false,"boldthemes_latest_posts":false,"boldthemes_grid_gallery":false},"uagb_author_info":{"display_name":"Jbednar","author_link":"https:\/\/www.mc-praha.cz\/mcp\/author\/jbednar\/"},"uagb_comment_info":0,"uagb_excerpt":"Firma Pfizer zavr\u0161ila v\u00fdvoj sv\u00e9 nejnov\u011bj\u0161\u00ed zbran\u011b proti COVID-19. Jedn\u00e1 se o l\u00e9k s vysokou [&hellip;]","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/www.mc-praha.cz\/mcp\/wp-json\/wp\/v2\/posts\/4168"}],"collection":[{"href":"https:\/\/www.mc-praha.cz\/mcp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mc-praha.cz\/mcp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mc-praha.cz\/mcp\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mc-praha.cz\/mcp\/wp-json\/wp\/v2\/comments?post=4168"}],"version-history":[{"count":1,"href":"https:\/\/www.mc-praha.cz\/mcp\/wp-json\/wp\/v2\/posts\/4168\/revisions"}],"predecessor-version":[{"id":4170,"href":"https:\/\/www.mc-praha.cz\/mcp\/wp-json\/wp\/v2\/posts\/4168\/revisions\/4170"}],"wp:attachment":[{"href":"https:\/\/www.mc-praha.cz\/mcp\/wp-json\/wp\/v2\/media?parent=4168"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mc-praha.cz\/mcp\/wp-json\/wp\/v2\/categories?post=4168"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mc-praha.cz\/mcp\/wp-json\/wp\/v2\/tags?post=4168"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}